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Recent studies have established speciﬁc cellular functions for different bioactive sphingolipids in skeletal
muscle cells. Ceramide 1-phosphate (C1P) is an important bioactive sphingolipid that has been involved
in cell growth and survival. However its possible role in the regulation of muscle cell homeostasis has not
been so far investigated. In this study, we show that C1P stimulates myoblast proliferation, as determined
by measuring the incorporation of tritiated thymidine into DNA, and progression of the myoblasts
through the cell cycle. C1P induced phosphorylation of glycogen synthase kinase-3b and the product of
retinoblastoma gene, and enhanced cyclin D1 protein levels. The mitogenic action of C1P also involved
activation of phosphatidylinositol 3-kinase/Akt, ERK1/2 and the mammalian target of rapamycin. These
effects of C1P were independent of interaction with a putative Gi-coupled C1P receptor as pertussis toxin,
which maintains Gi protein in the inactive form, did not affect C1P-stimulated myoblast proliferation. By
contrast, C1P was unable to inhibit serum starvation- or staurosporine-induced apoptosis in the
myoblasts, and did not affect myogenic differentiation. Collectively, these results add up to the current
knowledge on cell types targeted by C1P, which so far has been mainly conﬁned to ﬁbroblasts and
macrophages, and extend on the mechanisms by which C1P exerts its mitogenic effects. Moreover, the
biological activities of C1P described in this report establish that this phosphosphingolipid may be
a relevant cue in the regulation of skeletal muscle regeneration, and that C1P-metabolizing enzymes
might be important targets for developing cellular therapies for treatment of skeletal muscle degener-
ative diseases, or tissue injury.
 2011 Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Introduction
Skeletal muscle is mainly involved in active force production,
resulting in the movement of the skeletal system. Under normal
biological conditions adult skeletal muscle is an extremely stable
tissue. However, upon damage due to speciﬁc diseases, trauma or
strong physical exercise, skeletal muscle exhibits a remarkable1-phosphate; S1P, sphingo-
hatidylinositol 3-kinase; DTT,
edium; BSA, bovine serum
odium dodecylsulfate; PAGE,
n synthase kinase-3b; pRb,
n target of rapamycin; PTx,
Biochimiche, Università di
Italy. Tel.: þ390554598328;
nder CC BY-NC-ND license.capacity of self-repair. Repair and maintenance of skeletal muscle is
attributed to the skeletal muscle stem cell pool, represented by the
satellite cells. In response to a number of stimuli, quiescent satellite
cells become activated, start to proliferate and differentiate into
myoblasts, which then fuse to pre-existing myoﬁbres to regenerate
the tissue [1,2]. Although in the last decade much effort has been
dedicated to the comprehension of this key biological process,
improved understanding of the molecular mechanisms implicated
in skeletal muscle myogenesis is critical for the development of
therapies to reduce the loss of muscular mass associated with
muscle degenerative diseases, injuries, or aging.
In recent years sphingolipids have emerged as highly versatile
molecules acting both as structural components of the membrane
lipid bilayer and precursors of powerful bioactive signaling mole-
cules. Of note, sphingolipid mediators are capable of regulating
fundamental biological processes in a variety of tissues, including
skeletal muscle (for detailed reviews see [3,4]). In this regard, it was
reported that the plasma membrane content of sphingomyelin
(SM), which is the main sphingolipid in plasma membranes,
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porting the concept that SM hydrolysis produces signals that are
necessary for their activation [5]. A key bioactive sphingolipid
metabolite is ceramide, which can be formed via de novo synthesis
or through activation of sphingomyelinases and the subsequent
degradation of SM. Ceramide appears to be negatively associated
with myoblast differentiation, since inhibition of its de novo
synthesis enhances the onset of the differentiated phenotype in
cultured rat myoblasts [6]. Moreover, a number of recent studies
support the view that sphingosine 1-phosphate (S1P), another
powerful sphingoid mediator that can be generated by further
metabolism of ceramide, exerts a critical role in myogenesis.
Indeed, S1P has been found to mediate the entry of satellite cells
into the cell cycle, suggesting that the accelerated degradation of
SM observed upon cell activation leads to S1P production [7]. In
addition, challenging cultured C2C12myoblasts with S1P enhanced
their differentiation into myotubes without affecting their prolif-
erative state [8]. In agreement with this observation, sphingosine
kinase, the enzyme that produces S1P, has been described as pro-
myogenic for myoblasts [9], and was implicated in cytokine-
regulated myogenic differentiation [10].
Another key sphingolipid metabolite is ceramide 1-phosphate
(C1P), which is generated via direct phosphorylation of ceramide
by ceramide kinase (CERK). It was ﬁrst demonstrated that C1P
stimulated DNA synthesis in cultured rat ﬁbroblasts [11,12] as well
as in mouse macrophages [13]. Additionally, macrophage motility
and survival are robustly enhanced by treatment with C1P [14,15].
Also, this sphingolipid plays a key role in inﬂammatory responses.
In particular, C1P binds to and activates cytosolic phospholipase A2,
thus favoring prostanoid biosynthesis [16].
In this study, we demonstrate for the ﬁrst time that C1P stim-
ulates myoblast proliferation, an action that may be essential for
controlling muscle regeneration. This process implicates activation
of a whole panel of signal transduction pathways including phos-
phatidylinositol 3-kinase (PI3K)/Akt, ERK1/2, and mammalian
target of rapamycin (mTOR). Furthermore, although C1P promotes
macrophage survival, we here demonstrate that it does not inhibit
myoblast apoptosis, and that it is not involved in myoblast differ-
entiation. This study highlights skeletal muscle as a novel target
tissue for C1P, and suggests that this phosphosphingolipidmay play
an important role in skeletal muscle regeneration.
2. Materials and methods
2.1. Materials
Biochemicals, cell culture reagents, Dulbecco’s modiﬁed Eagle’s
medium (DMEM), fetal calf serum (FCS), protease inhibitor cocktail,
monoclonal anti-skeletal fast myosin heavy chain (MHC) (clone
MY-32), bovine serum albumin (BSA), staurosporine, LPA (synthe-
sized L-a-monooleoyl phosphatidic acid), C8-C1P, C16-C1P and
natural C1P were purchased from Sigma (St. Louis, MO, USA).
Mouse skeletal muscle C2C12 cells were obtained from the Amer-
ican Type Culture Collection, (Manassas, VA, USA). The ceramide-D-
erythro-1-phosphate [N-stearoyl-9,10-3H] (15 mM) was obtained
from American Radiolabeled Chemicals (Saint Louis, MO, USA) and
[g-33P]ATP was from Perkin Elmer (Waltham, MA, USA). Propidium
iodide and the ceramide kinase antibody were from Calbiochem
(San Diego, CA, USA). Pertussis toxin (PTx) was obtained fromAlexis
Corporation (San Diego, CA, USA). Monoclonal anti-caveolin-3 was
from Transduction Laboratories (Lexington, KY, USA). LY294002
hydrochloride, 10-DEBC hydrochloride, PD98059, U0126 and
rapamycinwere from Tocris Cookson Limited (Bristol, UK). TGX-221
was a kind gift of Prof. E. Hirsch (University of Turin, Italy). Anti-
bodies against myogenin (F5D), b-actin (C-11), cyclin D1 (72-13G),phosphorylated product of retinoblastoma gene (pRb) (Ser 795),
phosphorylated glycogen synthase kinase-3b (GSK-3b) (Ser 9), pan-
Akt (H-136), phospho-pan-Akt (Ser 473), anti-mouse, anti-rabbit,
and anti-goat immunoglobulin G1 conjugated to horseradish
peroxidase and Blotto (nonfat dry milk) were obtained from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Phospho-ERK1/2,
pan ERK1/2, phosphorylated mTOR (Ser 2448) antibodies were
from Cell Signaling Technology, Inc. (Beverly, MA, USA). Enhanced
chemiluminescence (ECL) reagents was obtained from Amersham
Pharmacia Biotech (Uppsala, Sweden). [3H]thymidine (20 Ci/mmol)
was from Perkin Elmer (Waltham, MA, USA). Fluorescein-
conjugated horse anti-mouse secondary antibody was obtained
from Vector (Burlingame, CA, USA). The caspase-3 substrate
Ac-DEVD-AFC was from Biomol Research Laboratories Inc. (PA,
USA). Annexin V-FITC apoptosis detection kit and phosphorylated
anti-GSK-3b (Tyr 216) were supplied by BD Biosciences (San Jose,
CA, USA). Speciﬁc CERK inhibitor NVP-231 [17] and the related
inactive compound 4 were kindly provided by Dr. F. Bornancin.
2.2. Cell culture
C2C12 mouse myoblasts were routinely grown in DMEM sup-
plemented with 10% FCS. For proliferation experiments, cells were
seeded in 12- or 6-well plates and used whenw40% conﬂuent. For
differentiation experiments, cells were seeded in 6-well plates and,
when conﬂuent, were shifted to DMEM without serum containing
1 mg/ml BSA. For apoptosis experiments myoblasts were seeded in
6-well plates and used when subconﬂuent.
2.3. Delivery of C1P to cells in culture
An aqueous dispersion of long-chain natural C1P (from bovine
brain, mainly containing stearic and nervonic fatty acids) was
added to cultured myoblasts as previously described [11]. Stock
solutions were prepared by sonicating C1P (1 mg) in sterile nano-
pure water (1 ml) on ice using a probe sonicator until a clear
dispersion was obtained. Final concentration of the stock solution
was approximately 1.47 mM.
2.4. Cell treatment with inhibitors
Speciﬁc inhibitors of PI3K, Akt, MEK andmTORwere administered
to the cells 30 min before agonist addition. Preliminarily, the speciﬁc
effect of various inhibitors was tested by Western Blot analysis, incu-
bating lysates from LY294002-, 10-DEBC-, TGX-221-, PD98059-,
U0126- or rapamycin-treated cells with anti-ERK1/2, anti-phospho-
ERK1/2, anti-Akt, anti-phospho-Akt or anti-phospho-mTOR anti-
bodies to verify the actual inhibition of the kinase activity. To inves-
tigate Gi-coupled events, C2C12 cells were incubated with 0.5 mg/ml
PTx for 16 h before C1P challenge.
2.5. Cell proliferation measurement
To evaluate [3H]thymidine incorporation, proliferating
myoblasts, previously serum-starved for 24 h, were challenged
with various concentrations of C1P for 16 h. In some instances cells
were pre-incubated for 30 min in the presence of appropriate
inhibitors before being stimulated with C1P for 16 h. [3H]thymidine
(0.5 mCi/well) was added for the last 2 h of incubation. Cells were
washed twice in ice-cold PBS before addition with 500 ml 10% tri-
chloroacetic acid for 5 min at 4 C. Cells were washed again in ice-
cold PBS, and 250 ml of ethanol:ether (3:1 v/v) was added to the
insoluble material. Samples were then lysed in 0.25 N NaOH for 1 h
at 37 C. Incorporation of [3H]thymidine was measured by scintil-
lation counting.
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Brieﬂy, proliferating myoblasts were serum-starved for 24 h and
then challenged with 15 mM C1P for 24 h before being trypsinized
and counted by a hemocytometer.
2.6. Cell cycle analysis
To investigate the cell cycle distribution, C2C12 myoblasts were
challenged with C1P for 16 h. Cell cycle distribution was deter-
mined by the propidium iodide-hypotonic citrate method with
a FACSCanto instrument (BectoneDickinson, San Jose, CA, USA)
essentially as previously described [18]. Brieﬂy, cells were washed
twice in PBS and collected by scraping in a solution containing
50 mg/ml propidium iodide, 0.1% sodium citrate and 0.1% Nonidet,
and analyzed 30 min later. The software used was ModFit LT for
Windows, Proliferation Protocol, Verity Software House Inc. (Top-
sham, ME, USA).
2.7. Western blot analysis
Cells were lysed for 30 min at 4 C in a buffer containing 50 mM
Tris, pH 7.5,120mMNaCl, 1mM EDTA, 6mM EGTA,15mMNa4P2O7,
20 mM NaF, 1% Nonidet, and protease inhibitor cocktail (1.04 mM
AEBSF, 0.08 mM aprotinin, 0.02 mM leupeptin, 0.04 mM bestatin,
15 mM pepstatin A, 14 mM E-64) essentially as described [8]. To
prepare total cell lysates, cell extracts were centrifuged for 15 min
at 10,000  g at 4 C. Protein aliquots (30 mg) from lysates were
resuspended in Laemmli’s sodium dodecylsulfate- (SDS) sample
buffer. Samples were subjected to SDS-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and Western analysis as previously
described [19]. Bound antibodies were detected using ECL reagents.
2.8. Cell immunoﬂuorescence assay
Cells were seeded on microscope slides, pre-coated with 2%
gelatine, and then treated or not with C1P. After 72 h cells were
ﬁxed in 2% paraformaldehyde in PBS for 20 min and permeabilized
in 0.1% Triton X-100-PBS for 30 min. Cells were then blocked in 3%
BSA for 1 h and incubated with anti-MHC antibody for 2 h and
ﬂuorescein-conjugated anti-mouse secondary antibody for 1 h. To
stain nuclei, the specimen was incubated with 50 mg/ml propidium
iodide in PBS for 15 min. Images were obtained using a Leica SP5
laser scanning confocal microscope with 40 objective. To quantify
the fusion of C2C12 cells after treatments, we calculated the fusion
index as the average number of nuclei in MHC-positive cells with at
least three nuclei above total number of nuclei.
2.9. Measurement of apoptosis
C2C12 myoblasts were seeded at a density of approximately
1  105 cells/well and employed for experiments after 24 h. For
serum starvation-induced apoptosis, cells were incubated in
serum-free medium for 24 h. In these experiments, C1P was
administered 30min and 18 h after serum starvation. Staurosporine
(0.5 mM) was added for the last 4 h of incubation to cells serum-
starved for 24 h, treated or not at 30 min and 18 h incubation
with C1P. Thapsigargin (3 mM) or etoposide (200 mM) were added
for the last 8 h of incubation to cells serum-starved for 24 h, treated
or not at 30 min and 18 h incubationwith C1P. To measure caspase-
3 activity cells were washed twice with PBS and then lysed for
20 min at 4 C in 20 mM TriseHCl buffer, pH 7.4, containing
250 mM NaCl, 2 mM EDTA, 0.1% Triton X-100, 5 mg/ml aprotinin,
5 mg/ml leupeptin, 0.5 mM phenylmethylsulfonyl ﬂuoride, 4 mM
sodium vanadate, and 1 mM dithiothreitol (DTT) essentially as
previously described [20]. Cell lysis was completed by sonication,and the total protein content was determined using the Coomassie
Blue reagent. Aliquots of protein (50 mg) were diluted in 50 mM
HEPES-KOH buffer (pH 7.0) containing 10% glycerol, 0.1% 3-[(3-
cholamidopropyl)-dimethylammonio]-1-propane sulfonate, 2 mM
EDTA, and 10 mM DTT. Caspase-3 activity was determined by
incubating protein samples for 2 h at 37 C with the ﬂuorescence
probe Ac-DEVD-AFC (30 mM) (excitation 400 nm, emission 505 nm)
as previously described [21]. To determine non speciﬁc substrate
degradation, the assays were also performed by preincubating total
protein samples for 15 min at 37 C with or without the speciﬁc
caspase inhibitor (200 nM Ac-DEVD-CHO) before substrate addi-
tion. Cell apoptosis was also measured by using an annexin V-FITC
apoptosis detection kit according to the manufacturer’s instruc-
tions (BD Biosciences). With this procedure, healthy cells remained
unstained whereas annexin V-FITC stained early apoptotic cells,
propidium iodide and annexin V-FITC stained late apoptotic cells
and propidium iodide stained necrotic cells. Samples were
analyzed by ﬂow cytometry with an air-cooled 488 nm argon-ion
laser (FACSCalibur, BD Biosciences) and CellQuest software (BD
Bioscences), essentially as described [22].
2.10. Evaluation of C1P metabolism in C2C12 cells
To examine C1P metabolism, C2C12 cells were treated with
50 nCi/ml of ceramide-D-erythro-1-phosphate [N-stearoyl-9,10-3H]
(15 mM). Then the cells were collected at different time points to
chase for the possible generation of C1P metabolites, mainly
ceramide, fatty acids, or sphingomyelin. The possible generation of
sphingosine 1-phosphate was evaluated using [33P]C1P (50 nCi/ml,
15 mM) which was synthesized according to a previously estab-
lished procedure [23]. Cells were washed twice with ice-cold
calcium-free PBS and scraped into 0.5 ml methanol. They were
thenwashed with a further 0.5 ml methanol, and the twomethanol
samples were combined and mixed with 0.5 ml chloroform. Lipids
were extracted by separation of phases with a further 0.5 ml
chloroform and 0.9 ml of a solution containing 2 M KCl and 0.2 M
HCl. Chloroform phases were dried under a stream of nitrogen and
lipids were separated by thin-layer chromatography using silica gel
60-coated glass plates. The plates were developed in a three solvent
system containing chloroform/methanol/ammonium hydroxide
(65:35:7.5, v/v/v); chloroform/methanol/acetic acid (9:1:1, v/v/v);
and butanol/acetic acid/water (3:1:1, v/v/v). The position of the
different lipids was identiﬁed after staining with I2 vapor by
comparison with authentic standards. Radioactivity was quantiﬁed
by scraping the spots from the plates by liquid scintillation
counting.
This work has been carried out in accordance with Uniform
Requirements for manuscripts submitted to Biomedical journals.
3. Results
3.1. C1P stimulates proliferation of C2C12 myoblasts
but does not affect cell differentiation or apoptosis
The aim of the present study was to examine whether C1P could
play a regulatory role of myoblast biological parameters. For this
purpose, we ﬁrst tested whether C1P was able to stimulate
myoblast proliferation. Fig. 1 shows that C1P stimulated DNA
synthesis, as determined by measuring the incorporation of [3H]
thymidine into DNA in C2C12 cells. This effect was concentration-
dependent and resulted to be optimum at 15 mM C1P. A similar
effect on cell proliferation was observed when pure C16-C1P was
employed instead of the C1P from bovine brain (see Materials and
methods section) (data not shown). In this study, we also used
a synthetic short-chain C1P (C8-C1P), which is more soluble in
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Fig. 1. Effect of C1P on [3H]thymidine incorporation. C2C12 myoblasts approximately
40% conﬂuent were serum-starved for 24 h. Cells were treated for 16 h with natural
C1P (solid square) or C8-C1P (open circle) at the indicated concentrations (0e30 mM).
[3H]thymidine incorporation into DNA was measured as described in the Methods
section. Data are means  SEM of at least three independent experiments per-
formed in triplicate. The effect of C1P was statistically signiﬁcant by Student’s t test
(*P < 0.05, **P < 0.01).
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synthesis elicited by C8-C1P was optimum at 10 mM. Given the
efﬁcacy of all these C1P species at stimulating DNA synthesis, the
natural C1P mixture was employed in all subsequent experiments.
To exclude that the observed mitogenic effect exerted by C1P
in the myoblasts was mediated by a bioactive metabolite gener-
ated following the addition of C1P to the cells, the metabolism of
[3H]C1P was examined at various time-intervals. Results presented
in Fig. 2 show that [3H]C1P was taken up by the myoblasts within
minutes reaching maximal incorporation after about 60 min of
incubation. Metabolism of C1P was very slow, with only traces of
free ceramide, fatty acids, or SM being detected up to at least 4 h
of incubation. These results are consistent with previous work
by Chalfant and co-workers [24] showing that C1P was rapidly
taken up by A549 cells with little metabolism to other compounds.
Also, similar results were obtained in ﬁbroblasts treated with
[3H]C8-C1P or with natural long-chain C1P [11,12]. Furthermore,
by using [33P]C1P it was evident that C1P was not deacylated to
S1P up to at least 4 h of incubation (data not shown). These latter0 5 30 60 120 240
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Fig. 2. Metabolism of labeled C1P in C2C12 cells. C2C12 myoblasts, approximately
40% conﬂuent, were serum-starved for 24 h and then exposed to 15 mM C1P
(100000 dpm/well) for the indicated times. Cell lipids were extracted and analyzed by
TLC as described in the Methods section. Results are expressed as the percentage of the
radioactivity present in the indicated lipids, ceramide (Cer), fatty acid (FA), C1P and
sphingomyelin (SM), compared to that in total lipids and are the mean  SEM of six
independent experiments performed in triplicate.results are in agreement with the well documented anti-mitogenic
effect exerted by S1P in myoblasts [8,18], in contrast to the mito-
genic effect of C1P observed in this work. Moreover, we found no
signiﬁcant amount of radioactivity in inorganic phosphate in the
culture medium of cells incubated with [33P]C1P for up to 4 h,
thereby ruling out any possible formation of ceramide by
dephosphorylation of [33P]C1P, in agreement with our previous
work [11,12,25].
Following up on the demonstration that the effect of C1P on
DNA synthesis was elicited by C1P per se, its mitogenic action was
further investigated by performing cell cycle analysis. Results pre-
sented in Fig. 3A show that in agreement with the studies on [3H]
thymidine incorporation, treatment of myoblasts with 15 mM C1P
approximately doubled the percentage of cells in S-phase, thereby
reinforcing the notion that C1P is a potent mitogenic agent for
myoblasts. Moreover, as shown in Fig. 3B, C1P was capable of
increasing myoblast number, thus behaving as a complete mitogen.
Interestingly, as shown in Fig. 3C, treatment of myoblasts with
15 mM C1P caused rapid phosphorylation of GSK-3b at Ser9 leading
to inactivation of its kinase activity. This effect could be detected as
early as 3 min and reached maximum value after about 30 min of
treatment with C1P. In addition, phosphorylation of GSK-3b at Tyr
216, which is responsible for stimulation of its kinase activity, was
moderately increased by C1P at 3 and 5 min, whereas it was
remarkably decreased at 90e120 min. Both pRb and cyclin D1 are
known to be maximally expressed throughout the G1 phase of the
cell cycle upon prevention of its GSK-3b-dependent proteolytic
degradation [26]. In accordancewith the observed phosphorylation
and inactivation of GSK-3b, challenge with C1P provoked hyper-
phosphorylation of pRb and prevented cyclin D1 from being
degraded in the myoblasts (Fig. 3D).
Althoughmyoblasts are endowedwith highmitogenic potential,
there are conditions when they can stop growing, initiate their
differentiation program, and become myotubes, multinucleated
cells. Therefore, we examined whether C1P could affect myoblast
differentiation. To this end, the expression of myogenic markers
such as MHC, myogenin, and caveolin-3 was evaluated by Western
blotting analysis of whole cell lysates that were prepared from
conﬂuent myoblasts. Fig. 4A shows that the expression of these
myogenic markers in unchallenged myoblasts was increased in
a time-dependent manner as a consequence of their progressive
myogenic differentiation [8]. Administration of 15 mM C1P to the
myoblasts did not affect the expression of any of the myogenic
markers at any time of incubation. Similar results were obtained
when 5 or 30 mM C1P were used (data not shown). Moreover, as
shown in the same Figure, C1P was unable to affect the fusion
index, which is used to assess the extent of myotube formation as
a result of the differentiation process.
It is known that C1P is also capable of protecting macrophages
from entering apoptosis [14,27,28]. Therefore, we examined
whether C1P could exert an anti-apoptotic action in C2C12 cells
incubated under apoptotic conditions (absence of serum in the
culture medium or long-term incubation with staurosporin).
Unexpectedly, the results presented in Fig. 4B clearly show that C1P
(15 mM) was unable to reduce the extent of caspase-3 activation in
serum-starved myoblasts or in cells that were treated with the pro-
apoptotic agent staurosporine (0.5 mM) for 4 h. Similarly, C1P was
ineffective to protect myoblasts from apoptosis induced by thap-
sigargin (3 mM) or by treatment with etoposide (200 mM), as
assessed by measuring caspase-3 activity (data not shown). In
agreement with these results, treatment with C1P did not inﬂuence
the percentage of cells in early or late apoptosis induced by serum
deprivation. This was assessed using cells that were labeled with
propidium iodide and annexin V-FITC in combination with ﬂow
cytometry (Fig. 4B).
Fig. 3. Effect of C1P on cell cycle and cell number. C2C12 myoblasts approximately 40% conﬂuent were serum-starved for 24 h. A) To assess cell cycle distribution serum-starved
C2C12 myoblasts were treated or not with 15 mM C1P for 16 h. Cellular DNAwas stained with propidium iodide (50 mg/ml) and cell cycle analysis was performed by ﬂow cytometry.
Data are means  SEM of three independent experiments. The effect of C1P was statistically signiﬁcant by Student’s t test (*P < 0.05). B) Serum-starved myoblasts were stimulated
with 15 mM C1P for 24 h before being counted by a hemocytometer. Data are means  SEM of three independent experiments performed in duplicate. The effect of C1P was
statistically signiﬁcant by Student’s t test (*P < 0.05). C2C12 cells were incubated for the indicated times in the presence of 15 mM C1P. Cell lysates were then subjected to
immunoblotting to detect phospho-GSK-3b (Ser9) and phospho-GSK-3b (Tyr216) (C), phospho-pRb and cyclin D1 (D). Equally loaded protein was checked by expression of the
nonmuscle-speciﬁc b isoform of actin. Blots representative of at least three independent experiments are shown. The histograms represent band intensity of phospho-GSK-3b
(Ser9), phospho-GSK-3b (Tyr216), P-pRb and cyclin D1 normalized to b-actin and reported as mean  SEM of three independent experiments, fold change over control set as 1. The
effect of C1P was statistically signiﬁcant by Student’s t test (*P < 0.05).
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Fig. 4. Effect of C1P on C2C12myoblast differentiation (A) and apoptosis (B). A) Conﬂuent C2C12 myoblasts were incubated in medium supplemented with 0.1% BSA for the indicated
period of time in the absence () or in the presence (þ) of 15 mMC1P. Upper panel:Western blot analysis ofmyogenicmarker expression. The content ofmyogenin, myosin heavy chain
(MHC), and caveolin-3 (cav-3) was analyzed in cell lysates (30 mg) byWestern Blot analysis. Equally loaded protein was checked by expression of the nonmuscle-speciﬁc b isoform of
actin. A blot representative of four independent experiments with analogous results is shown. The histograms represent band intensity of MHC, myogenin, and cav-3 normalized to b-
actin and reported asmean SEMof four independent experiments, fold change over control (time 24h, no addition) set as 1. The effect of C1Pwas statistically signiﬁcant by Student’s t
test (*P< 0.05). Lower panel: Representative immunoﬂuorescence images of C2C12myoblasts treated for 72 h with 15 mMC1P stained with anti-MHC antibody and propidium iodide
are shown. Fusion index represented in the histogramwas calculated as described in the Methods section. Data are means  SEM of four independent experiments. B) The apoptotic
responsewas induced by 24 h serum starvation or 4 h treatmentwith 0.5 mMstaurosporine in subconﬂuentmyoblasts treated or notwith 15 mMC1P. Left panel: caspase-3 activitywas
measured employing a ﬂuorimetric method. Data are means  SEM of three independent experiments performed in duplicate and are reported as fold increase in caspase-3 activity
relative to the value measured in control cells set as 1. Right panel: cells were examined for necrosis or early or late apoptosis by ﬂow cytometry analysis as described in the Methods
section. Results are expressed as percentage of cells and are the mean  SEM of three independent experiments performed in duplicate.
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Fig. 5. Role of C1P-induced activation of Akt, ERK1/2 and mTOR (A) on DNA synthesis (B), and cyclin D1 expression (C) in C2C12 myoblasts. C2C12 myoblasts approximately 40%
conﬂuent were serum-starved for 24 h and incubated with or without 15 mM C1P for the indicated time-intervals. A) Cell lysates were separated by SDS-PAGE and immunoblotted
using speciﬁc anti-phospho-Akt, anti-pan Akt, anti-phospho-ERK1/2, anti-pan ERK1/2, anti-phospho-mTOR and anti-b-actin antibodies. Blots representative of at least three
independent experiments are shown. In the histograms band intensity corresponding to phosphorylated protein was normalized to its total content or to b-actin and reported as
mean  SEM of three independent experiments, fold change over control set as 1. The effect of C1P was statistically signiﬁcant by Student’s t test (*P < 0.05). B) C2C12 cells were
pre-treated for 30 min with PI3K inhibitor (5 mM LY294002) or Akt inhibitor (1 mM 10-DEBC) or MEK inhibitor (5 mM U0126 or 5 mM PD98059) or mTOR inhibitor (10 nM rapamycin)
before being challenged with 15 mM C1P for 16 h. [3H]thymidine incorporation into DNA was measured as described in the Methods section. Data are means  SEM of three
independent experiments performed in triplicate. The effect of C1P was statistically signiﬁcant by Student’s t test (**P < 0.01); the effect of the inhibitors was statistically signiﬁcant
by Student’s t test (#P < 0.05). C) Western Blot analysis of cyclin D1 expression. C2C12 cells were pre-treated 30 min with PI3K/Akt speciﬁc inhibitor (5 mM LY294002) or
MEK/ERK1/2 speciﬁc inhibitor (5 mM U0126) or mTOR inhibitor (10 nM rapamycin) before being challenged (þ) or not () with 15 mM C1P for 8 h. Cell extracts were subjected to
immunoblotting. Equally loaded protein was checked by expression of the nonmuscle-speciﬁc b isoform of actin. A blot representative of at least three independent experiments is
shown. The histogram represents band intensity of cyclin D1 normalized to b-actin and reported as mean  SEM of three independent experiments, fold change over control set as
1. The effect of C1P was statistically signiﬁcant by Student’s t test (*P < 0.05); the effect of the inhibitors was statistically signiﬁcant by Student’s t test (#P < 0.05).
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Fig. 6. Effect of PTx on C1P mitogenic effect in C2C12 myoblasts. A) C2C12 myoblasts
approximately 40% conﬂuent were serum-starved for 24 h. C2C12 cells were pre-
incubated for 16 h with PTx (0.5 mg/ml) before being challenged with 15 mM C1P.
[3H]thymidine incorporation into DNA after 16 h of treatment with 15 mM C1P was
measured as described in the Methods section. Data are means  SEM of three
independent experiments performed in triplicate. The effect of C1P was statistically
signiﬁcant by Student’s t test (**P < 0.01). Inset: conﬂuent C2C12 myoblasts were pre-
treated 16 h with PTx (0.5 mg/ml) before being challenged (þ) or not () with 10 mg/ml
LPA for 48 h. The content of myogenin and caveolin-3 (cav-3) was analyzed in cell
lysates (30 mg) by Western Blot analysis. Equally loaded protein was checked by
expression of the nonmuscle-speciﬁc b isoform of actin. A blot representative of three
independent experiments with analogous results is shown. B) Effect of PTx on
C1P-induced activation of Akt and ERK1/2. Serum-starved myoblasts were pre-
incubated for 16 h with PTx (0.5 mg/ml) before being challenged with 15 mM C1P for
10 min. Cell lysates were analyzed by Western Blotting as described in Methods
section. A representative blot of three independent experiments is shown. Histo-
grams represent densitometric quantiﬁcation of phosphorylated protein normalized to
its total content and reported as mean  SEM of three independent experiments, fold
change over control set as 1. The effect of C1P was statistically signiﬁcant by Student’s
t test (*P < 0.05).
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of PI3K/Akt, ERK1/2 and mTOR
To gain insight into the mechanism by which C1P stimulates
myoblast proliferation, we examined whether this phosphos-
phingolipid could activate signaling pathways speciﬁcally impli-
cated in the regulation of cell growth. Western blotting analyses of
phospho-Akt, phospho-ERK1/2 and phospho-mTOR performed on
lysates obtained frommyoblasts treated with 15 mMC1P for various
time-intervals demonstrate that all of the investigated signaling
pathways were transiently activated by C1P. In particular, Akt and
mTOR phosphorylation was maximal at 5 min, while ERK1/2 were
maximally activated at 10 min (Fig. 5A). To examine the possible
role of these pathways in C1P-mediated myoblast proliferation,
[3H]thymidine incorporation experiments were performed in
myoblasts previously incubated in the presence of selective inhib-
itors of these pathways. As depicted in Fig. 5B, inhibition of PI3K
with 5 mM LY294002 or blockade of Akt with 1 mM 10-DEBC,
abolished the mitogenic action of C1P; similarly, this sphingolipid
was unable to stimulate myoblast proliferation when ERK1/2 acti-
vationwas prevented by treatment with the MEK inhibitors UO126
(5 mM) or PD98059 (5 mM), or when mTOR activation was blocked
by treatment with rapamycin (10 nM). The data presented in Fig. 5C
show that inhibition of MEK/ERK1/2, PI3K/Akt, or mTOR by UO126,
LY294002, or rapamycin, respectively, also blunted the enhance-
ment of cyclin D1 levels elicited by C1P at 8 h of incubation. Given
that the activation of these signaling pathways is often detected
following membrane receptor(s) engagement and that C1P was
shown to stimulate migration of RAW 264.7 macrophages in
a PTx-sensitive manner [15], we examined whether the mitogenic
action of C1P could be mediated by a Gi protein-coupled receptor.
Myoblast treatment with 0.5 mg/ml PTx for 16 h did not affect the
mitogenic response to 15 mM C1P (Fig. 6A), nor did it alter the
extent of Akt or ERK1/2 phosphorylation (Fig. 6B). In contrast, as
shown in the inset of Fig. 6A, the anti-myogenic effect of 10 mg/ml
LPA, mediated through interaction with a Gi protein-coupled
receptor [29], is signiﬁcantly reduced by the pre-treatment with
0.5 mg/ml PTx for 16 h. Therefore, it is unlikely that C1P-stimulated
myoblast growth is mediated by a receptor of this kind.
In an attempt to establish a possible cross-talk among the various
signaling pathways that were activated by C1P and found to be
implicated in its pro-mitogenic action, the effect of C1P on the
individual signaling pathways in the presence of different inhibitors
was examined. Results presented in Fig. 7 show that pre-incubation
with 5 mM UO126 prevented C1P-induced ERK1/2 phosphorylation
at 10 min of incubation. Moreover, this inhibitor did not reduce Akt
phosphorylation indicating that ERK1/2 signaling is not upstreamof
the PI3K/Akt pathway. Interestingly, the blockade of ERK1/2
pathway abolished the enhancement of mTOR phosphorylation,
demonstrating that in this setting ERK1/2 is upstream of mTOR
activation, in keeping with the key role of this kinase in the inhi-
bition of its main suppressor, TSC2 [30]. The same Figure shows that
the blockade of PI3K with LY294002 blunted Akt phosphorylation
and largely decreased ERK1/2 and mTOR activation, strongly sug-
gesting that PI3K/Akt is partially upstream of ERK1/2. To establish
whether mTOR activation by C1P is downstream of PI3K/Akt
signaling pathway, TGX-221, a selective inhibitor of PI3Kb, which
does not affect mTOR activity was employed [31]. Interestingly,
myoblast treatment with 1 mM TGX-221 resulted in a nearly
complete inhibition of Akt phosphorylation, demonstrating that
PI3Kb is the major PI3K isoform implicated in the signaling cascade
triggered by C1P;moreover, in this experimental condition, C1Pwas
not capable of further increasing mTOR phosphorylation, whose
basal levels were enhanced, therefore proving that PI3Kb is
upstream of mTOR activation by this sphingolipid.Finally, the role of endogenous C1P in C2C12 myoblasts was
investigated. Cell treatment with the CERK inhibitor NVP-231
(100 nM) reduced [3H]thymidine incorporation by approximately
30%, highlighting the involvement of CERK in C2C12 cell prolifer-
ation (Fig. 8A). However, the protein content of CERK was not
altered during myoblast proliferation or differentiation (Fig. 8B)
excluding a role for the transcriptional regulation of this enzyme in
these biological processes.4. Discussion
The proliferation of skeletal muscle progenitor cells such as
satellite cells and myoblasts is an essential step in the repair of
damaged tissue since increases in the number of these cells ensures
an adequate repopulation of the tissue. Although there has been
Fig. 7. C1P-induced activation of mTOR is downstream of PI3K/Akt and ERK1/2 signaling pathways in C2C12 myoblasts. C2C12 myoblasts approximately 40% conﬂuent were serum-
starved for 24 h and pre-incubated for 30 min with PI3K inhibitor (5 mM LY294002) or MEK inhibitor (5 mM U0126) or PI3Kb inhibitor (1 mM TGX-221) before being challenged with
15 mM C1P for 10 min. Cell lysates were separated by SDS-PAGE and immunoblotted using speciﬁc anti-phospho-Akt, anti-pan Akt anti-phospho-ERK1/2, anti-pan ERK1/2, anti-
phospho-mTOR and anti-b-actin antibodies. Blots representative of at least three independent experiments are shown. Histograms represent densitometric quantiﬁcation of
phosphorylated protein normalized to its total content or to b-actin and reported as mean  SEM of three independent experiments, fold change over control set as 1. The effect of
C1P was statistically signiﬁcant by Student’s t test (*P < 0.05); the effect of the inhibitors was statistically signiﬁcant by Student’s t test (#P < 0.05).
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implicated in the regulation of this key event have not been fully
characterized [32]. In this work we have identiﬁed C1P as positive
regulator of mouse skeletal myoblast proliferation. Several pieces of
experimental evidence are here provided for the mitogenic effect of
C1P in these cells. This phosphosphingolipid potently stimulated
[3H]thymidine incorporation into DNA, cell cycle progression and
cell number. Moreover, C1P enhanced GSK3-b and pRb phosphor-
ylation as well as cyclin D1 protein content. However, other critical
biological functions of myoblasts, such as myogenic differentiation
or cell survival, appear to be unaffected by C1P. This phosphos-
phingolipid was previously found to promote cell survival in
macrophages (reviewed in [28,33]); therefore, the present report
supports the notion that C1P evokes a speciﬁc response in
myoblasts. Notably, the mitogenic action of C1P in myoblasts was
elicited by the bioactive compound per se and could not be attrib-
utable to any possible mediator formed by C1Pmetabolism in these
cells.
So far only few cell types (mainly different types of macro-
phages) are known to respond to natural (long-chain) C1P [28,33].
The present demonstration that C1P enhances cell growth ofmouse
myoblasts extends the number of target cells that are responsive to
C1P and supports the notion that C1P, besides acting as a mediatorof the inﬂammatory response, can also participate in other
key biological processes such as myogenesis. Intriguingly, other
sphingolipids are known to regulate speciﬁc aspects of skeletal
muscle cell physiology. In particular, S1P is known to stimulate
myoblast differentiation toward myotubes [8] and to inhibit their
chemotactic response [34]. By contrast sphingosine, its immediate
precursor, was reported to inhibit chickenmyoblast fusion [35], and
de novo synthesized ceramide was found to be responsible for
inhibition of myogenic differentiation of rat myoblasts [6]. Thus,
C1P appears to be the only sphingolipid endowed with mitogenic
properties in myoblasts at the present time, providing strong
evidence that sphingolipids are critical for regulation of skeletal
muscle development and regeneration, and reinforcing the notion
that individual bioactive sphingolipids play speciﬁc and distinct
roles in the control of this highly orchestrated biological process.
In this study, the molecular mechanisms by which C1P stimu-
lates C2C12 cell proliferation were also investigated. The PI3K/Akt
and ERK1/2 signaling pathways were found both necessary for the
mitogenic response to C1P, since selective inhibition of these
kinases abrogated the biological action of this sphingolipid. Inter-
estingly, the mitogenic response elicited by C1P was equally pre-
vented when mTOR was selectively blocked, supporting the view
that this kinase, which was here identiﬁed downstream of PI3K/Akt
Fig. 8. Role of endogenous C1P on C2C12 myoblast proliferation and differentiation. A) C2C12 myoblasts approximately 40% conﬂuent were serum-starved for 24 h before being
treated with CERK inhibitor (100 nM NVP-231) or the related inactive compound (100 nM compound 4). [3H]thymidine incorporation into DNA was measured as described in the
Methods section. Data are means  SEM of three independent experiments performed in triplicate. The effect of CERK inhibitor was statistically signiﬁcant by Student’s t test
(*P < 0.05). B) C2C12 myoblasts approximately 40% conﬂuent were serum-starved for 24 h and incubated with or without 10% FBS for the indicated time-intervals (upper panel) or
grown to conﬂuence and incubated in medium supplemented with 0.1% BSA for the indicated period of time (lower panel). Cell lysates were separated by SDS-PAGE and
immunoblotted using speciﬁc anti-CERK and anti-b-actin antibodies. Blots representative of three independent experiments are shown. The histograms represent band intensity of
CERK normalized to b-actin and reported as mean  SEM of three independent experiments, fold change over control set as 1.
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Thus, these results further consolidate the well-established role
exerted by PI3K/Akt, mTOR and ERK1/2 in the regulation of
myoblast proliferation [36e41] and highlight C1P as a critical
metabolite implicated in the control of myoblast proliferation as
key regulator of these kinases. In accordance with the ﬁndings
presented in this report, the PI3K/Akt and ERK1/2 pathways were
also identiﬁed as mediators of the mitogenic effect of C1P in bone
marrow-derived macrophages [13], suggesting a common mecha-
nism of action of C1P in macrophages and myoblasts. By contrast,
C1P was found to exert a mitogenic action in ﬁbroblasts via an
ERK-independent mechanism [12], reinforcing the notion that this
bioactive sphingolipid exploits distinct signaling pathways in
different cellular settings for eliciting its biological response. Also,
contrary to the pro-survival role of C1P in macrophages and
although C1P stimulates Akt, and ERK1/2 in myoblasts, C1P did not
inhibit apoptosis in these cells.
The rapid time-course of signaling cascades triggered by C1P in
myoblastsmight inprinciple, be consistentwith a receptor-mediatedevent. In this connection, C1P was shown to stimulate macrophage
migration through interaction with a Gi protein-coupled receptor
[15]; however, the involvement of such a receptor in the mitogenic
effect of C1P in myoblasts was ruled out by the inability of PTx to
block C1P-dependent ERK1/2 or Akt phosphorylation, and cell
proliferation. In agreement with these observations, PTx also failed
to prevent the mitogenic and anti-apoptotic responses elicited by
C1P in bone marrow-derived macrophages [14], where the mito-
genic effect of C1P seems to be associated to the generation of
intracellular C1P [42]. Nonetheless, a possible involvement of
receptors other than Gi protein-coupled receptors in the mitogenic
effect of C1P in myoblasts remains to be determined.
It is well established that endogenous C1P is formed intracel-
lularly by ceramide kinase-catalyzed phosphorylation of ceramide
[43,44], although other pathways may also exist [45]. The potential
ability of mouse myoblasts to synthesize C1P by their own, which
would act as an endogenous regulator of their own proliferation,
was not explored here; however, the described mitogenic response
of myoblasts to C1P added exogenously strongly supports the
P. Gangoiti et al. / Biochimie 94 (2012) 597e607 607hypothesis that C1P released by other cells, such as macrophages,
which are recruited to the sites of muscle damage [46e48],
might participate to the beneﬁcial effect of muscle growth and
regeneration.
In summary, we show here that C1P promotes proliferation of
mouse myoblasts, strongly suggesting the involvement of this
sphingolipid in the regulation of muscle regeneration and repair.Acknowledgments
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